文献速递肝病

艾尔巴韦/格拉瑞韦在丙型肝炎病毒感染合并代偿性肝硬化患者中的安全性与疗效:一项整合分析

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
PubMed 文献 · Gastroenterology · 2017-02-11

该整合分析纳入6项临床试验中402例基因1、4或6型丙型肝炎病毒感染合并Child-Pugh A级代偿性肝硬化患者,所有患者接受艾尔巴韦/格拉瑞韦50 mg/100 mg每日一次治疗,联合或不联合利巴韦林,疗程12-18周。主要终点为治疗结束后12周持续病毒学应答(SVR12),定义为HCV RNA <15 IU/mL。初治和经治患者接受12周艾尔巴韦/格拉瑞韦治疗的SVR12率分别为97.8%(135/138)和88.9%(48/54);在12周方案中加入利巴韦林未提高初治患者(90.3%,28/31)或经治患者(91.4%,74/81)的SVR12率。所有(49/49)接受艾尔巴韦/格拉瑞韦联合利巴韦林16或18周的经治患者以及93.9%(46/49)接受艾尔巴韦/格拉瑞韦不联合利巴韦林16或18周的患者达到SVR12。基因1a型感染患者的病毒学失败率高于基因1b或4型感染患者,尤其是在既往干扰素治疗无应答的患者中。基线耐药相关替换(RASs)检测指导个体化选择疗程,并确立了对基因1a型感染且存在RASs的患者(无论治疗史)联用利巴韦林的需求。在基因1a型感染且基线HCV非结构蛋白5A存在RASs的患者中,接受12周艾尔巴韦/格拉瑞韦治疗者73%(8/11)达到SVR12,而无基线RASs者98%(96/98)达到SVR12。两例基因1a型感染且基线存在RASs的患者接受16或18周艾尔巴韦/格拉瑞韦联合利巴韦林治疗均达到SVR12。在接受艾尔巴韦/格拉瑞韦治疗的患者中,2.3%(6/264)报告了无症状的丙氨酸氨基转移酶和天冬氨酸氨基转移酶3级或4级升高。3%(8/264)报告了严重不良事件,无患者发生失代偿相关事件。结论:在6项临床试验数据的分析中,基因1、4或6型感染合并代偿性肝硬化患者接受艾尔巴韦/格拉瑞韦联合或不联合利巴韦林治疗的SVR12率为89%至100%。在12周艾尔巴韦/格拉瑞韦方案中加入利巴韦林对初治或经治患者达到SVR12的比例影响甚微。然而,当艾尔巴韦/格拉瑞韦联合利巴韦林疗程延长至16或18周时,经治患者中未发生病毒学失败。基线RASs分析(或无该检测时干扰素无应答史)可用于确定基因1a型感染患者的疗程和是否需要利巴韦林。

要点

  • 初治和经治患者接受12周艾尔巴韦/格拉瑞韦的SVR12率分别为97.8%(135/138)和88.9%(48/54)。
  • 12周方案中加入利巴韦林未提高初治(90.3%,28/31)或经治(91.4%,74/81)患者的SVR12率。
  • 经治患者接受艾尔巴韦/格拉瑞韦联合利巴韦林16或18周均达到SVR12(49/49)。

核心结论

  • 在6项临床试验数据的分析中,基因1、4或6型感染合并代偿性肝硬化患者接受艾尔巴韦/格拉瑞韦联合或不联合利巴韦林治疗的SVR12率为89%至100%。
  • 在12周艾尔巴韦/格拉瑞韦方案中加入利巴韦林对初治或经治患者达到SVR12的比例影响甚微。
  • 当艾尔巴韦/格拉瑞韦联合利巴韦林疗程延长至16或18周时,经治患者中未发生病毒学失败。
  • 基线RASs分析(或无该检测时干扰素无应答史)可用于确定基因1a型感染患者的疗程和是否需要利巴韦林。

研究设计与样本

  • 对6项临床试验中402例基因1、4或6型HCV感染合并Child-Pugh A级代偿性肝硬化患者进行整合分析。
  • 所有患者接受艾尔巴韦/格拉瑞韦50 mg/100 mg每日一次,联合或不联合利巴韦林,疗程12-18周。
  • 主要终点为治疗结束后12周持续病毒学应答(SVR12),定义为HCV RNA <15 IU/mL。

主要发现

  • 初治和经治患者接受12周艾尔巴韦/格拉瑞韦的SVR12率分别为97.8%(135/138)和88.9%(48/54)。
  • 接受12周艾尔巴韦/格拉瑞韦联合利巴韦林的初治患者SVR12率为90.3%(28/31),经治患者为91.4%(74/81)。
  • 经治患者接受艾尔巴韦/格拉瑞韦联合利巴韦林16或18周的SVR12率为100%(49/49),不联合利巴韦林16或18周为93.9%(46/49)。
  • 基因1a型感染且基线NS5A RASs阳性者接受12周艾尔巴韦/格拉瑞韦的SVR12率为73%(8/11),无基线RASs者为98%(96/98)。
  • 2.3%(6/264)患者报告无症状的ALT和AST 3级或4级升高,3%(8/264)报告严重不良事件,无失代偿相关事件。

关键数值与推荐

  • SVR12定义为治疗结束后12周HCV RNA <15 IU/mL。
  • 艾尔巴韦/格拉瑞韦剂量为50 mg/100 mg每日一次,联合或不联合利巴韦林,疗程12-18周。
  • 基因1a型感染且存在基线RASs的患者(无论治疗史)需联用利巴韦林。

临床怎么用

  • 基线RASs检测(或无该检测时干扰素无应答史)可用于指导基因1a型感染患者的疗程选择和利巴韦林联用决策。
  • 对于经治患者,艾尔巴韦/格拉瑞韦联合利巴韦林延长至16或18周可达到100%(49/49)的SVR12率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials. METHODS: We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials. All patients received elbasvir/grazoprevir 50 mg/100 mg once daily, with or without ribavirin, for 12-18 weeks. The primary end point was sustained virologic response 12 weeks after completion of therapy (SVR12), defined as a level of HCV RNA <15 IU/mL. RESULTS: Among treatment-naïve and treatment-experienced patients receiving elbasvir/grazoprevir for 12 weeks, 97.8% (135 of 138) and 88.9% (48 of 54) achieved SVR12, respectively. Among patients receiving elbasvir/grazoprevir for 12 weeks, addition of ribavirin did not increase the proportion of treatment-naïve patients (90.3%, 28 of 31) or treatment-experienced patients who achieved an SVR12 (91.4%, 74 of 81). All (49 of 49) treatment-experienced patients receiving elbasvir/grazoprevir with ribavirin for 16 or 18 weeks, and 93.9% (46 of 49) of patients receiving elbasvir/grazoprevir without ribavirin for 16 or 18 weeks achieved SVR12. Virologic failure was higher among patients with HCV genotype 1a infections compared with patients with genotype 1b or 4 infections, particularly in patients who had not responded to previous interferon therapy. Baseline tests for resistance-associated substitutions (RASs) led to an individualized approach for selecting treatment duration and established a need for ribavirin for patients with HCV genotype 1a infection and RASs, regardless of treatment history. Among patients with HCV genotype 1a infection with and without baseline RASs in HCV nonstructural protein 5A who received elbasvir/grazoprevir for 12 weeks, 73% (8 of 11) and 98% (96 of 98) achieved SVR12, respectively. Both patients with HCV genotype 1a infection with baseline RASs who received 16 or 18 weeks of elbasvir/grazoprevir and ribavirin achieved SVR12. Grade 3 or 4 increases in levels of alanine aminotransferase and aspartate aminotransferase, which did not cause symptoms, were reported in 2.3% (6 of 264) of patients receiving elbasvir/grazoprevir. Serious adverse events were reported in 3% (8 of 264) patients and no patient had a decompensation-related event. CONCLUSIONS: In an analysis of data from 6 clinical trials, rates of SVR12 ranged from 89% to 100% in patients with HCV genotype 1, 4, or 6 infections and compensated cirrhosis treated with elbasvir/grazoprevir, with or without ribavirin. Addition of ribavirin to a 12-week regimen of elbasvir/grazoprevir had little effect on the proportion of treatment-naïve or treatment-experienced patients who achieved an SVR12. However, virologic failure did not occur in any treatment-experienced patients when the duration of elbasvir/grazoprevir and ribavirin therapy was extended to 16 or 18 weeks. Baseline analysis of RASs (or in the absence of this test, a history of nonresponse to interferon) can be used to determine treatment duration and the need for ribavirin in patients with HCV genotype 1a infection. Clinicaltrials.gov ID: NCT02092350, NCT02105662, NCT02105467, NCT02105701, NCT01717326, and NCT02105454.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Jacobson IM, Lawitz E, Kwo PY, et al. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Gastroenterology. 2017. PMID: 28193518. doi:10.1053/j.gastro.2017.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。